PATENT CLAIM ANALYSIS

Application Number: 15909576
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "282000"]

Abstract:
Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action μ-opioid receptor antagonist/-ϰ-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a μ-opioid receptor antagonist or prodrug thereof, and a ϰ-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Claim (Index 2):
The method of  claim 1 , wherein said dual action mu-opioid receptor antagonist/kappa-opioid receptor agonist is selected from the group consisting of Nalbuphine, Butorphanol, Pentazocine Nalorphine, Naltriben, Alazocine, Atomoxetine, Bremazocine, Salvinorin A, Samidorphan, Nalmefene, Nalodeine and combinations of two or more thereof, and their prodrugs.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.5814
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14113340', '13445716', '13024298', '14390322', '14170791']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7679651640143994
- 35 USC 102 Novelty (BERT): 0.5392606339938667
- Combined Prediction Score: 0.7450947110123461
- Mean Citation Score: 268.39056600000004
- Max Citation Score: 365.56586
- Similarity Product: 295.22380583566434

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test